GOLDSTONE ASIA PHARM: Diclofenac Sodium Sustained-Release Tablets Pass Consistency Evaluation
I'm PortAI, I can summarize articles.
GOLDSTONE ASIA PHARM's wholly-owned subsidiary, Zhejiang Di'er Pharmaceutical, recently received approval from the National Medical Products Administration for the sodium diclofenac sustained-release tablets (0.1g) to pass the consistency evaluation of quality and efficacy for generic drugs. This medication is suitable for alleviating acute episodes of chronic arthritis such as rheumatoid arthritis and osteoarthritis, as well as various soft tissue rheumatic pains
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments